These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25106074)

  • 1. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
    Dolton MJ; McLachlan AJ
    Int J Antimicrob Agents; 2014 Sep; 44(3):183-93. PubMed ID: 25106074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
    Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
    Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole.
    Vreugdenhil B; van der Velden WJFM; Feuth T; Kox M; Pickkers P; van de Veerdonk FL; Blijlevens NMA; Brüggemann RJM
    Br J Clin Pharmacol; 2018 Sep; 84(9):1980-1988. PubMed ID: 29744898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections.
    Resztak M; Zalewska P; Wachowiak J; Sobkowiak-Sobierajska A; Główka FK
    Eur J Clin Pharmacol; 2024 Nov; 80(11):1829-1840. PubMed ID: 39240338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.
    Karthaus M; Lehrnbecher T; Lipp HP; Kluge S; Buchheidt D
    Ann Hematol; 2015 Apr; 94(4):547-56. PubMed ID: 25697592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity.
    Veloso DFMC; Benedetti NIGM; Ávila RI; Bastos TSA; Silva TC; Silva MRR; Batista AC; Valadares MC; Lima EM
    Drug Deliv; 2018 Nov; 25(1):1585-1594. PubMed ID: 30044149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population.
    Dapía I; García I; Martinez JC; Arias P; Guerra P; Díaz L; García A; Ochoa D; Tenorio J; Ramírez E; Román M; Gordo G; Saiz-Rodríguez M; Frías J; Abad-Santos F; Lapunzina P; Carcas AJ; Borobia AM
    Int J Antimicrob Agents; 2019 Oct; 54(4):463-470. PubMed ID: 31279853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Plasma Trough Concentration of Voriconazole and Voriconazole N-Oxide in Its Hepatotoxicity in Adult Patients.
    Cheng L; You X; Wang X; Yu M; Jia C
    Drug Des Devel Ther; 2024; 18():3617-3628. PubMed ID: 39156484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Cutaneous Aspergillosis in a Preterm Infant.
    Frick MA; Boix H; Camba Longueira F; Martin-Gomez MT; Rodrigo-Pendás JÁ; Soler-Palacin P
    Pediatr Infect Dis J; 2016 Jun; 35(6):704-6. PubMed ID: 26974892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.
    Job KM; Olson J; Stockmann C; Constance JE; Enioutina EY; Rower JE; Linakis MW; Balch AH; Yu T; Liu X; Thorell EA; Sherwin CM
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):731-46. PubMed ID: 27355512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
    Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY
    Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
    Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
    J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 is involved in the effect of Wuzhi tablet (
    Yuan F; Liang X; Chen X; Qin X; Tan C; Wang L
    Pharmazie; 2020 Nov; 75(11):559-564. PubMed ID: 33239129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
    Howard A; Hoffman J; Sheth A
    Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.
    Elewa H; El-Mekaty E; El-Bardissy A; Ensom MH; Wilby KJ
    Clin Pharmacokinet; 2015 Dec; 54(12):1223-35. PubMed ID: 26070947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isavuconazole: Case Report and Pharmacokinetic Considerations.
    Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
    Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of the pharmacokinetic/pharmacodynamic relationship in the treatment of invasive aspergillosis with voriconazole. Reduced drug toxicity through novel rapid release formulations.
    Gallego-Arranz T; Pérez-Cantero A; Torrado-Salmerón C; Guarnizo-Herrero V; Capilla J; Torrado-Durán S
    Colloids Surf B Biointerfaces; 2020 Sep; 193():111119. PubMed ID: 32464356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
    Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
    Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.
    Martin JM; Macias-Parra M; Mudry P; Conte U; Yan JL; Liu P; Capparella MR; Aram JA
    Pediatr Infect Dis J; 2017 Jan; 36(1):e1-e13. PubMed ID: 27636722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.